Chauhan P, Bhargava A, Kumari R, Ratre P, Tiwari R, Kumar Srivastava R, Yu Goryacheva I, Kumar Mishra P. Surface-enhanced Raman scattering biosensors for detection of oncomiRs in breast cancer.
Drug Discov Today 2022;
27:2121-2136. [PMID:
35460892 DOI:
10.1016/j.drudis.2022.04.016]
[Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Revised: 03/03/2022] [Accepted: 04/13/2022] [Indexed: 12/16/2022]
Abstract
Surface-enhanced Raman scattering (SERS) has emerged as one of the most promising platforms for various biosensing applications. These sensing systems encompass the advantages of specificity, ultra-high sensitivity, stability, low cost, repeatability, and easy-to-use methods. Moreover, their ability to offer a molecular fingerprint and identify the target analyte at low levels make SERS a promising technique for detecting circulating cancer biomarkers with greater sensitivity and reliability. Among the various circulating biomolecules, oncomiRs are emerging as prominent biomarkers for the early screening of breast cancers (BCs). In this review, we provide a comprehensive understanding of different SERS-based biosensors and their application to identify BC-specific oncomiRs. We also discuss different SERS-based sensing strategies, nano-analytical frameworks, and challenges to be addressed for effective clinical translation.
Collapse